This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.08% per year. These returns cover a period from January 1, 1988 through May 6, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Agios' (AGIO) Q4 Loss In Line, Revenues Surpass Estimates
by Zacks Equity Research
Agios' (AGIO) loss meets estimates in the fourth quarter of 2020 while revenues beat the same. Sale of leukemia drug, Tibsovo, rise both sequentially as well as year over year. Shares down.
Agios Pharmaceuticals (AGIO) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Are Options Traders Betting on a Big Move in Agios (AGIO) Stock?
by Zacks Equity Research
Investors need to pay close attention to Agios (AGIO) stock based on the movements in the options market lately.
Agios (AGIO) to Sell Oncology Drugs to Servier for $2B, Stock Up
by Zacks Equity Research
Agios (AGIO) sells its oncology business unit to French company Servier for around $2 billion. The company plans to solely focus on developing treatments for genetically defined diseases. Shares rise.
Agios Pharmaceuticals (AGIO) Up 6.2% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Agios' (AGIO) Phase III Study on Mitapivat Meets Primary Goal
by Zacks Equity Research
Agios' (AGIO) phase III ACTIVATE study evaluating mitapivat for addressing PK deficiency in patients with no regular blood transfusions achieves the primary goal.
Agios' (AGIO) Mitapivat Gets Orphan Drug Tag to Treat SCD
by Zacks Equity Research
The FDA confers an orphan drug status on Agios' (AGIO) pyruvate kinase-R activator mitapivat for addressing sickle cell disease. Stock climbs in after-hours trading.
Agios' (AGIO) Q3 Loss Wider Than Expected, Revenues Miss
by Zacks Equity Research
Agios' (AGIO) earnings and revenues fall shy of estimates in the third quarter. The company lifts the lower end of 2020 sales guidance for its leukemia drug Tibsovo. Stock inches up.
Agios Pharmaceuticals (AGIO) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Agios Pharmaceuticals (AGIO) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Agios (AGIO) Withdraws Filing for Leukemia Drug Tibsovo in EU
by Zacks Equity Research
Agios (AGIO) withdraws the regulatory filing for Tibsovo in Europe, which was developed to treat relapsed/refractory acute myeloid leukemia in adult patients with a susceptible IDH1 mutation.
All You Need to Know About Agios Pharmaceuticals (AGIO) Rating Upgrade to Buy
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Agios Pharmaceuticals (AGIO) Down 15.5% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of 7.75% and 5.62%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Agios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Agios Pharmaceuticals (AGIO) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Has Agios Pharmaceuticals (AGIO) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (AGIO) Outperforming Other Medical Stocks This Year?
Agios Gets Orphan Drug Tag for Mitapivat to Treat Thalassemia
by Zacks Equity Research
The FDA confers an orphan drug status on Agios' (AGIO) pyruvate kinase-R activator mitapivat for addressing patients with thalassemia. Stock rises in after-hours trading.
Why Is Agios Pharmaceuticals (AGIO) Up 25.8% Since Last Earnings Report?
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Moving Average Crossover Alert: Agios Pharmaceuticals
by Zacks Equity Research
Agios Pharmaceuticals, Inc. (AGIO) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
Is Agios Pharmaceuticals (AGIO) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (AGIO) Outperforming Other Medical Stocks This Year?
Will Agios Pharmaceuticals Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor Agios Pharmaceuticals
Why Agios (AGIO) Stock Might be a Great Pick
by Zacks Equity Research
Agios (AGIO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Agios' (AGIO) Q1 Loss Narrower Than Expected, Revenues Beat
by Zacks Equity Research
Agios' (AGIO) loss and revenues better estimates in Q1. The company's wholly owned leukemia drug Tibsovo sees a sequential rise in sales.
Agios Pharmaceuticals (AGIO) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of 65.29% and 182.24%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?